CUSIP: 67001K202
Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
12,994,304
-
Share change
-
+12,982,308
-
Total reported value
-
$109,401,000
-
Put/Call ratio
-
13%
-
Price per share
-
$8.42
-
Number of holders
-
59
-
Value change
-
+$109,300,003
-
Number of buys
-
58
Quarterly Holders Quick Answers
What is CUSIP 67001K202?
CUSIP 67001K202 identifies NVLNF - NOVELION THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 67001K202:
Institutional Holders of NOVELION THERAPEUTICS INC - COM NEW (NVLNF) as of Q4 2016
As of 31 Dec 2016,
NOVELION THERAPEUTICS INC - COM NEW (NVLNF) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,994,304 shares.
The largest 10 holders included
Broadfin Capital, LLC, Stonepine Capital Management, LLC, ARMISTICE CAPITAL, LLC, SCOPIA CAPITAL MANAGEMENT LP, Sarissa Capital Management LP, Healthcare Value Capital, LLC, FMR LLC, KINGSTOWN CAPITAL MANAGEMENT L.P., Ancora Advisors, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.